Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.10) per share which beat the an

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected

BURLINGTON, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Entry into a Material Definitive Agreement.On May 27, 2026, Minerva Neurosciences, Inc. (the "Co

Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, whi

The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technicall

BURLINGTON, Mass. , May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a c

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.17) per share which missed the

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and firs

Citizens analyst Jason N. Butler initiates coverage on Minerva Neurosciences (NASDAQ:NERV) with a

Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) was the recipient of a large growth in s

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remai

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remai

BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a c

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company

Minerva Neurosciences (NASDAQ: NERV) provided an update on its development program for roluperidone,

HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

$200,000,000Common StockPreferred StockDebt SecuritiesWarrantsFrom time to time, we may offer and se

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.64) per share which missed the

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negativ

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a c

UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are

Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will a

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences

U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Wednesday.

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings f

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesda

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders

Gainers

  On Friday, 153 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.